Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models

Journal of Medicinal Chemistry

Volumn 48, Issue 12, 2005, Pages 4049-4060

  Rivara, Silvia ^a   Lorenzi, Simone ^a   Mor, Marco ^a   Plazzi, Pier Vincenzo ^a   Spadoni, Gilberto ^b   Bedini, Annalida ^b   Tarzia, Giorgio ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; N[(1 BENZENESULFONYL 4 METHOXY 1H INDOL 2 YL)METHYL]PROPIONAMIDE; N[1(4 CHLOROBENZYL) 4 METHOXY 1H INDOL 2 YLMETHYL]PROPIONAMIDE; N[[1(4 CHLOROBENZOYL) 4 METHOXY 1H INDOL 2 YL]METHYL]PROPIONAMIDE; RECEPTOR BLOCKING AGENT; UCM 454; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHOBICITY; MOLECULAR DYNAMICS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CATTLE; HUMANS; INDOLES; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 20444363062     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm048956y     Document Type: Article

References (71)

1. Lerner, A. B.; Case, J. D. Structure of melatonin. J. Am. Chem. Soc. 1959, 81, 6084-6085.
2. Pevet, P.; Bothorel, B.; Slotten, H.; Saboureau, M. The chronobiotic properties of melatonin. Cell Tissue Res. 2002, 309, 183-191.
3. 2 receptors in rat suprachiasmatic nucleus phase advances the arcadian clock. Am. J. Physiol.: Cell Physiol. 2001, 280, C110-C118.
4. Dubocovich, M. L.; Rivera-Bermudez, M. A.; Gerdin, M. J.; Masana, M. I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci. 2003, 8, d1093-d1108.
5. Guerrero, J. M.; Reiter, R. J. Melatonin-immune system relationships. Curr. Top. Med. Chem. 2002, 2, 167-179.
6. Doolen S.; Krause, D. N.; Dubocovich, M. L.; Duckles, S. P. Melatonin mediates two distinct responses in vascular smooth muscle. Eur. J. Pharmacol. 1998, 345, 67-69.
7. (a) Savaskan, E.; Olivieri, G.; Meier, F.; Brydon, L.; Jockers, R.; Ravid, R.; Wirz-Justice, A.; Muller-Spahn, F. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res. 2002, 32, 59-62.
8. + current inhibition. J. Pineal Res. 2004, 36, 109-116.
9. Kadekaro, A. L.; Andrade, L. N. S.; Floeter-Winter, L. M.; Rollag, M. D.; Virador, V.; Wieira, W.; Castrucci A. M. d. L. MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J. Pineal Res. 2004, 36, 204-211.
10. 1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 355, 365-375.
11. Delagrange, P.; Atkinson, J.; Boutin, A.; Casteilla, L.; Lesieur, D.; Misslin, R.; Pellissier, S.; Pénicaud, L.; Renard, P. Therapeutic perspectives for melatonin agonists and antagonists. J. Neuroendocrinol. 2003, 15, 442-448.
12. i: precoupling and constitutive activity. Mol. Pharmacol. 1999, 56, 1014-1024.
13. 2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation. J. Med. Chem. 2003, 46, 1429-1439.
14. 1 melatonin receptor partial agonists, antagonists, and putative inverse agonists. J. Med. Chem. 1998, 41, 3624-3634.
15. 2-selective melatonin antagonists. J. Med. Chem. 2001, 44, 2900-2912.
16. Gatti, G.; Piersanti, G., Spadoni, G. Conformation by NMR of two tetralin-based receptor ligands. Farmaco 2003, 58, 469-476.
17. 2 melatoninergic ligands. Bioorg. Med. Chem. 2003, 11, 753-759.
18. 2 melatonin receptor selective ligands. J. Med. Chem. 2002, 45, 2788-2800.
19. 2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 553-561.
20. Lucini, V.; Pannacci, M.; Scaglione, F.; Fraschini, F.; Rivara, S.; Mor, M.; Bordi, F.; Plazzi, P. V.; Spadoni, G.; Bedini, A.; Piersanti, G.; Diamantini, G.; Tarzia, G. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. J. Med. Chem. 2004, 47, 4202-4212.
21. Faust, R.; Garratt, P. J.; Jones, R.; Yeh, L.-K.; Tsotinis, A.; Panoussopoulou, M.; Calogeropoulou, T.; Teh, M.-T.; Sugden, D. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J. Med. Chem. 2000, 43, 1050-1061.
22. 1 melatoninergic ligands. J. Med. Chem. 2003, 46, 1127-1129.
23. Morgan, P. J.; Lawson, W.; Davidson, G.; Lowell, H. E. Guanine nucleotides regulate the affinity of melatonin receptors on the ovine pars tuberalis. Neuroendocrinology 1989, 50, 359-362.
24. Masana, M. I.; Dubocovich, M. L. Melatonin receptor signaling: finding the path through the dark. Sci STKE 2001, 107, PE39.
25. Reppert, S. M.; Weaver, D. R.; Ebisawa, T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994, 13, 1177-1185.
26. 1b receptor. Proc. Natl. Acad. Sci. 1995, 92, 8734-8738.
27. Reppert, S. M.; Weaver, D. R.; Godson, C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci. 1996, 17, 100-102.
28. 1aβ melatonin receptor. Biochem. Biophys. Res. Commun. 1997, 239, 418-423.
29. Kokkola, T.; Foord, S. M.; Watson, M.-A.; Vakkuri, O.; Laitinen, J. T. Important amino acids for the function of the human MT1 melatonin receptor. Biochem. Pharmacol. 2003, 65, 1463-1471.
30. 1 receptor. Biochem. Biophys. Res. Commun. 2001, 282, 1229-1236.
31. 2 melatonin receptor. Biochem. Pharmacol. 2003, 65, 315-320.
32. 1 and melatonin-related receptors. J. Biol. Chem. 2000, 275, 20602-20609.
33. Gubitz, A. K.; Reppert, S. M. Chimeric and point-mutated receptors reveal that a single glycine residue in transmembrane domain 6 is critical for high affinity melatonin binding. Endocrinology 2000, 141, 1236-1244.
34. Grol, C. J.; Jansen, J. M. The high affinity melatonin binding site probed with conformationally restricted ligands-II. Homology modeling of the receptor. Bioorg. Med. Chem. 1996, 4, 1333-1339.
35. Sugden, D.; Chong, N. W. S.; Lewis, D. F. V. Structural requirements at the melatonin receptor. Br. J. Pharmacol. 1995, 114, 618-623.
36. Navajas, C.; Kokkola, T.; Poso, A.; Honka, N.; Gynther, J.; Laitinen, J. T. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. Eur. J. Pharmacol. 1996, 304, 173-183.
37. Uchikawa, O.; Fukatsu, K.; Tokunoh, R.; Kawada, M.; Matsumoto, K.; Imai, Y.; Hinuma, S.; Kato, K.; Nishikawa, H.; Hirai, K.; Miyamoto, M.; Ohkawa, S. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J. Med. Chem. 2002, 45, 4222-4239.
38. Ivanov, A. A.; Voronkov, A. E.; Baskin, I. I.; Palyulin, V. A.; Zefirov, N. S. The study of the mechamism of binding of human ML1A melatonin receptor ligands using molecular modeling. Dokl. Biochem. Biophys. 2004, 394, 49-52.
39. Mazna, P.; Obsilova, V.; Jelinkova, I.; Balik, A.; Berka, K.; Sovova, Z.; Ettrich, R.; Svoboda, P.; Obsil, T.; Teisinger, J. Molecular modeling of MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding. J. Neurochem. 2004, 91, 836-842.
40. Tsotomu, M.; Ryohei, K.; Haruo, T.; Satoshi, N.; Keisuke, T.; Satoru, M.; Tominaga, F.; Takamasa, U.; Hideharu, S.; Makoto, S.; Yoshiaki, K.; Hideya, H. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 1999, 42, 1789-1802.
41. Okada, T.; Sugihara, M.; Bondar, A.-N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. J. Mol. Biol. 2004, 342, 571-583.
42. Baldwin, J. M.; Schertler, G. F. X.; Unger, V. M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 1997, 272, 144-164.
43. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 1995, 25, 366-428.
44. Ballesteros, J. A.; Shi, L.; Javitch, J. A. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60, 1-19.
45. 3 receptor. J. Pharmacol. Exp. Ther. 2002, 301, 451-458.
46. 1 receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem. 2003, 46, 5139-5152.
47. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
48. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
49. 2 receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 5881-5884.
50. 1A receptor. Int. J. Quantum Chem. 1997, 63, 767-780.
51. Mor, M.; Spadoni, G.; Di Giacomo, B.; Diamantini, G.; Bedini, A.; Tarzia, G.; Plazzi, P. V.; Rivara, S.; Nonno, R.; Lucini, V.; Panacci, M.; Fraschini, F.; Stankov, B. M. Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. Bioorg. Med. Chem. 2001, 9, 1045-1057.
52. Visiers, I.; Ballesteros, J. A.; Weinstein, H. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol. 2002, 343, 329-371.
53. 2 Adrenergic receptor activation. J. Biol. Chem. 2002, 277, 40989-40996.
54. Hulme E. C.; Lu, Z.-L.; Ward, S. D. C.; Allman, K.; Curtis, C. A. M. The conformational switch in 7-transmembrane receptors: the muscarinic paradigm. Eur. J. Pharmacol. 1999, 375, 247-260.
55. 1a receptor following stable transfection into NIH3T3 cells. Br. J. Pharmacol. 1998, 124, 485-492.
56. 1-antagonists. Br. J. Pharmacol. 1999, 127, 1288-1294.
57. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Anal. Biochem. 1976, 72, 248-254.
58. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
59. Sybyl, version 6.9; Tripos Inc.: St. Louis, MO, 2001.
60. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
61. Halgren, T. A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20, 720-729.
62. Halgren, T. A. Merck molecular force field. I. Basis, from, scope, parametrization and performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
63. Polak, E.; Ribière, G. Note sur la convergence de directions conjugées. Rev. Fr. Informat. Recherche Opertionelle 1969, 16, 35-43.
64. Boekmann, B.; Bairoch, A.; Apweiler, R.; Blatter, M.-C.; Estreicher, A.; Gasteiger, E.; Martin, M. J.; Michoud, K.; O'Donovan, C.; Phan, I.; Pilbout, S.; Schneider, S. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res, 2003, 31, 365-370.
65. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680.
66. Herman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
67. Allen, F. H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr. 2002, B58, 380-388.
68. The Scripps Research Institute, La Jolla, CA.
69. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
70. Connolly, M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983, 221, 709-713.
71. Heiden, W.; Moeckel, G.; Brickmann J. A new approach to the display of local lipophilicity/hydrophilicity mapped on molecular surfaces. J. Comput.-Aided Mol. Des. 1993, 7, 503-514.